PORTON PHARMA SOLUTIONS LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.97 CNY | +1.64% |
|
+6.90% | -28.55% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,767 | 19,821 | 48,697 | 22,305 | 13,735 | 9,812 | - | - |
| Enterprise Value (EV) 1 | 7,767 | 19,821 | 48,697 | 22,305 | 13,735 | 9,812 | 9,812 | 9,812 |
| P/E ratio | 40.9 x | 60.9 x | 92.2 x | 11.1 x | 51.3 x | -3,594 x | 19.8 x | 35.2 x |
| Yield | 0.73% | 0.33% | 0.22% | 2.71% | 1.94% | 1.32% | 1.73% | - |
| Capitalization / Revenue | 5.01 x | 9.57 x | 15.7 x | 3.17 x | 3.75 x | 3.22 x | 2.18 x | 2.23 x |
| EV / Revenue | 5.01 x | 9.57 x | 15.7 x | 3.17 x | 3.75 x | 3.22 x | 2.18 x | 2.23 x |
| EV / EBITDA | 24.9 x | 41 x | 66.4 x | 8.9 x | 23.4 x | 15.5 x | 9.26 x | 10.4 x |
| EV / FCF | - | - | - | 1,60,16,985 x | - | - | - | - |
| FCF Yield | - | - | - | 0% | - | - | - | - |
| Price to Book | 2.53 x | 5.84 x | 12.2 x | 3.72 x | 2.37 x | 1.73 x | 1.51 x | 1.65 x |
| Nbr of stocks (in thousands) | 5,42,748 | 5,42,748 | 5,44,405 | 5,46,027 | 5,46,120 | 5,46,038 | - | - |
| Reference price 2 | 14.31 | 36.52 | 89.45 | 40.85 | 25.15 | 17.97 | 17.97 | 17.97 |
| Announcement Date | 25/02/20 | 24/02/21 | 28/02/22 | 24/03/23 | 26/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,551 | 2,072 | 3,105 | 7,035 | 3,667 | 3,052 | 4,498 | 4,404 |
| EBITDA 1 | 311.8 | 483.9 | 733.8 | 2,507 | 588 | 634.5 | 1,060 | 948 |
| EBIT 1 | 194.7 | 352.2 | 565.6 | 2,265 | 268.9 | -43 | 540.6 | 263 |
| Operating Margin | 12.55% | 17% | 18.21% | 32.2% | 7.33% | -1.41% | 12.02% | 5.97% |
| Earnings before Tax (EBT) 1 | 193.4 | 363.7 | 548.8 | 2,246 | 246.6 | -53 | 531.9 | 243 |
| Net income 1 | 185.6 | 324.4 | 523.9 | 2,005 | 266.9 | -3.5 | 495.6 | 277 |
| Net margin | 11.96% | 15.66% | 16.87% | 28.51% | 7.28% | -0.11% | 11.02% | 6.29% |
| EPS 2 | 0.3500 | 0.6000 | 0.9700 | 3.690 | 0.4900 | -0.005000 | 0.9071 | 0.5100 |
| Free Cash Flow | - | - | - | 1,393 | - | - | - | - |
| FCF margin | - | - | - | 19.8% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | 55.56% | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | 69.44% | - | - | - | - |
| Dividend per Share 2 | 0.1040 | 0.1210 | 0.1930 | 1.106 | 0.4870 | 0.2380 | 0.3100 | - |
| Announcement Date | 25/02/20 | 24/02/21 | 28/02/22 | 24/03/23 | 26/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1,304 | 1,817 | 3,121 | 1,378 | 960.9 | 698.3 | 630.4 | 677.7 | 1,118 | 590 | 822 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | 515.7 | 877.2 | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | 28.38% | 28.11% | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | 510.6 | 867.3 | - | - | - | - | - | - | - | - |
| Net income | 830.4 | - | 427.7 | 793.1 | - | - | - | - | - | - | - | - |
| Net margin | - | - | 23.53% | 25.41% | - | - | - | - | - | - | - | - |
| EPS | 1.510 | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 19/08/22 | 25/10/22 | 24/03/23 | 24/03/23 | 21/04/23 | 18/08/23 | 27/10/23 | 26/04/24 | 26/04/24 | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | 1,393 | - | - | - | - |
| ROE (net income / shareholders' equity) | 6.25% | 10.1% | 14.2% | 40.3% | 4.6% | -0.05% | 7% | 4.7% |
| ROA (Net income/ Total Assets) | - | - | 7.98% | 24% | - | 1.7% | 5.18% | - |
| Assets 1 | - | - | 6,562 | 8,353 | - | -205.9 | 9,571 | - |
| Book Value Per Share 2 | 5.650 | 6.250 | 7.310 | 11.00 | 10.60 | 10.40 | 11.90 | 10.90 |
| Cash Flow per Share 2 | 0.6500 | 0.9300 | 0.8900 | 4.700 | 1.150 | 1.320 | 1.500 | 1.620 |
| Capex 1 | 170 | 393 | 770 | 1,172 | 1,128 | 689 | 688 | - |
| Capex / Sales | 10.98% | 18.97% | 24.8% | 16.66% | 30.74% | 22.59% | 15.29% | - |
| Announcement Date | 25/02/20 | 24/02/21 | 28/02/22 | 24/03/23 | 26/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
17.97
CNY
Average target price
26.65
CNY
Spread / Average Target
+48.30%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.55% | 1.34B | |
| +32.36% | 698B | |
| +26.51% | 568B | |
| -4.40% | 358B | |
| +19.46% | 328B | |
| +3.50% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +8.62% | 165B |
- Stock Market
- Equities
- 300363 Stock
- Financials Porton Pharma Solutions Ltd.